Skip to main content

Table 1 Patient Demographics and Baseline Characteristics

From: Long-term effectiveness and safety of infliximab and golimumab in ankylosing spondylitis patients from a Canadian prospective observational registry

  IFX GLM
Number of Patients 389 421
Male Gender, n (%) 244 (62.7%) 249 (59.1%)
Mean (SD) Age, years 45.6 (11.9) 45.7 (13.3)
Mean (SD) Weight, Kg 79.8 (18.4) 81.9 (18.3)
Disease Duration
 Mean (SD) 8.6 (9.8) 6.0 (10.1)
 Median 4.0 1.6
HLA B27, n/N (%) 27/42 (64.2%) 47/62 (75.8%)
Uveitis, n/N (%)
 History 19/67 (28.3%) 53/369 (14.3%)
 If yes, present? 3/19 (15.7%) 4/46 (8.7%)
Psoriasis, n (%)
 History 8/66 (12.1%) 58/376 (15.4%)
 If yes, present? 6/8 (75.0%) 40/56 (71.4%)
Inflammatory Bowel Disease, n (%)
 History 11/67 (16.4%) 33/373 (8.8%)
 If yes, present? 8/9 (88.9%) 21/32 (65.6%)
Peripheral Arthritis, n (%)
 History 20/67 (30.0%) 143/373 (38.3%)
 If yes, present? 13/18 (72.2%) 115/137 (83.9%)
Presence of Enthesitis (n/N, %) 21/360 (5.5%) 135/340 (39.7%)
Presence of dactylitis (n/N, %) 8/241 (3.3%) 31/235 (13.2%)
Previous Therapies (n, %)
 NSAIDs 302, 77.6% 343, 81.5%
 Corticosteroids 97, 24.9% 97, 23.0%
 DMARDs 99, 25.4% 61, 22.8%
Concomitant Therapies (n, %)
 NSAIDs 251, 64.5% 281, 66.8%
 Corticosteroids 44, 11.3% 51/421, 12.1%
 MTX 79, 20.3% 41/421 (9.7%)
Bio-naive, % 91.3% 82.7%
BASDAI
 Available n 374 405
 Median 6.5 6.5
 Mean (SD, 95% C.I) 6.3 (2.2, 6.1–6.5) 6.1 (2.1, 5.9–6.3)
BASFI
 Available n 374 403
 Median 6.3 5.6
 Mean (SD, 95% C.I) 5.9 (2.5, 5.7–6.2) 5.3 (2.4, 5.1–5.6)
PtGA
 Available n 96 256
 Median 64 70
 Mean (SD, 95% C.I) 59.4 (27.8, 53.8–65.1) 61.6 (24.6, 58.5–64.6)
MDGA
 Available n 385 414
 Median 7.0 6.0
 Mean (SD, 95% C.I) 6.3 (2.1, 6.1–6.5) 5.5 (2.1, 5.3–6.0)
HAQ
 Available n 376 399
 Median 1.1 1.0
 Mean (SD, 95% C.I) 1.2 (0.6, 1.1–1.2) 1.0 (0.6, 1.0–1.1)
CRP (mg/ml)
 Available n 312 319
 Median 9.0 5.9
 Mean (SD, 95% C.I) 18.0 (27.8, 14.9–21.1) 14.8 (30.9, 11.4–18.2)
ESR (mm/hr)
 Available n 333 308
 Median 18.0 12.0
 Mean (SD, 95% C.I) 23.5 (20.7, 21.3–25.8) 17.2 (15.5, 15.4–18.9)
ASDAS
 Mean (SD, 95% C.I)) 3.7 (1.1, 3.6–3.8) 3.4 (1.0, 3.3–3.5)
 Median 3.8 3.4
 Inactive (% < 1.3) 2.4% 2.7%
 Moderate (% 1.3–2.0) 3.9% 7.5%
 High (% 2.1–3.5) 35.5% 48.1%
 Very High (% > 3.5) 58.3% 38.3%